CAR-T(CAR-T)细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CAR-T(CAR-T)细胞在血液系统恶性肿瘤中的应用推动了这种免疫治疗形式的显著进展。
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
英文原题:Unmet needs and lived experience of patients receiving CAR T-cell therapy.
Unmet needs and lived experience of patients receiving CAR T-cell therapy.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
CAR-T 细胞疗法是治疗血液系统恶性肿瘤的有效疗法和前景广阔的前沿方向。然而,这一革命性治疗也给患者、照护者和医疗系统带来了新的挑战。在这篇综述文章中,我们讨论患者在CAR-T 输注后急性和长期阶段面临的各种困难。我们重点介绍应对这些困难的各种方式,以及为改善患者体验所需进一步开展的研究和支持领域。此外,我们还考虑照护者和医疗系统所承受的困难和负担,以及获得CAR-T 治疗的障碍。最后,我们讨论未来研究和干预开发的方向,以满足患者和照护者的需求并改善公平可及性。我们提出,将专科姑息治疗早期整合到接受CAR-T 治疗的患者及其照护者中,是一项有前景的策略,有助于改善患者体验并满足其需求。
Chimeric Antigen Receptor T-Cell (CAR-T) therapy is an effective therapy and promising frontier in the treatment of hematologic malignancies.
However, this revolutionary treatment has led to new challenges for patients, caregivers, and the healthcare system. In this review article, we discuss the various difficulties patients face both in the acute and long-term period following CAR-T infusion.
We highlight the various ways these difficulties are addressed, as well as further areas of research and support needed to improve patient experience.
Additionally, we consider the difficulties and burdens placed on caregivers and healthcare systems, as well as barriers to accessing CAR-T therapy.
Finally, we address future directions of research and intervention development to meet patient and caregiver needs and improve equitable access.
We pose early integration of specialty palliative care for individuals and their caregivers undergoing CAR-T therapy as one promising strategy to help improve patient experience and meet their needs.
MEMBER ACCOUNT
登录成功会直接打开下一页。